Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955

CTLA-4 Control over Foxp3 + Regulatory T Cell Function

Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4

Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233

Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation

Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206

Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses

Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,785

Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575

Modulation of tryptophan catabolism by regulatory T cells

Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M., & Puccetti, P. (2003) · Nature Immunology · doi:10.1038/ni1003 · Cited by 1,375

Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., & Nakayama, E. (1999) · PubMed · Cited by 1,062

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345

Cancer immunotherapy via dendritic cells

Palucka, K., & Banchereau, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3258 · Cited by 2,109

Immunotherapies for hepatocellular carcinoma

Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472

Targeting metastasis

Steeg, P. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.25 · Cited by 1,363

Immune Checkpoint Inhibitors in Cancer Therapy

Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,347

Monoclonal antibodies: versatile platforms for cancer immunotherapy

Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature reviews. Immunology · doi:10.1038/nri2744 · Cited by 1,339

CTLA-4: a moving target in immunotherapy

Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,100

Lung cancer immunotherapy: progress, pitfalls, and promises

Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102

Regulatory T cells in tumor immunity

Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944

Combination cancer immunotherapies tailored to the tumour microenvironment

Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944

Cancer nanomedicine for combination cancer immunotherapy

Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 955

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

Quezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., Muranski, P., Antony, P. A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091918 · Cited by 898

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857

IL-35-mediated induction of a potent regulatory T cell population

Collison, L. W., Chaturvedi, V., Henderson, A. L., Giacomin, P., Guy, C. S., Bankoti, J., Finkelstein, D., Forbes, K., Workman, C. J., Brown, S. A., et al. (2010) · Nature Immunology · doi:10.1038/ni.1952 · Cited by 870

Dendritic-Cell-Based Therapeutic Cancer Vaccines

Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

Gettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0593 · Cited by 787

The Next Decade of Immune Checkpoint Therapy

Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750

The head and neck cancer immune landscape and its immunotherapeutic implications

Mandal, R., Şenbabaoğlu, Y., Desrichard, A., Havel, J. J., Dalin, M. G., Riaz, N., Lee, K.-W., Ganly, I., Hakimi, A. A., Chan, T. A.-T., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89829 · Cited by 785

Molecular Mechanisms of Treg-Mediated T Cell Suppression

Schmidt, A., Oberle, N., & Krammer, P. H. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00051 · Cited by 814

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

Carter, P. J., & Lazar, G. A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 780

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

Duraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 750

Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells

De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani, V., Politano, C., Bonnal, R. J. P., Provasi, E., Sarnicola, M. L., Panzeri, I., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.021 · Cited by 687

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

Ott, P. A., Hodi, F. S., & Robert, C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0143 · Cited by 706

Clinical blockade of PD1 and LAG3 — potential mechanisms of action

Nguyen, L. T., & Ohashi, P. S. (2014) · Nature reviews. Immunology · doi:10.1038/nri3790 · Cited by 634

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S. B., Horak, C., Weber, J. S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3342 · Cited by 579

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0833 · Cited by 594

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592

Anti-TIM3 Antibody Promotes T Cell IFN-γ–Mediated Antitumor Immunity and Suppresses Established Tumors

Ngiow, S. F., von Scheidt, B., Akiba, H., Yagita∥, H., Teng, M. W. L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0096 · Cited by 588

Immunological landscape and immunotherapy of hepatocellular carcinoma

Prìeto, J., Melero, I., & Sangro, B. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.173 · Cited by 573

Regulatory circuits of T cell function in cancer

Speiser, D. E., Ho, P., & Verdeil, G. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.80 · Cited by 570

Immune checkpoints and their inhibition in cancer and infectious diseases

Dyck, L., & Mills, K. H. G. (2017) · European Journal of Immunology · doi:10.1002/eji.201646875 · Cited by 553

Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints

Chang, L., Barroso‐Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 550

Application of PD-1 Blockade in Cancer Immunotherapy

Wu, X., Gu, Z., Yang, C., Chen, B., Chen, W., Weng, L., & Liu, X. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.006 · Cited by 541

Immune Modulation in Cancer with Antibodies

Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P., & Wolchok, J. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112807 · Cited by 523

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons

Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L. P., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 547

OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients

Curti, B. D., Kovacsovics-Bankowski, M., Morris, N. P., Walker, E., Chisholm, L., Floyd, K., Walker, J. M., Gonzalez, I. L., Meeuwsen, T., Fox, B. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4174 · Cited by 503

Chemokines in Cancer

Chow, M. T., & Luster, A. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0160 · Cited by 509

Cancer immunotherapies: advances and bottlenecks

Rui, R., Zhou, L., & He, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212476 · Cited by 484

B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer

Hollern, D. P., Xu, N., Thennavan, A., Glodowski, C. R., García‐Recio, S., Mott, K. R., He, X., Garay, J. P., Carey-Ewend, K., Marron, D. L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.028 · Cited by 480

Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma

Winograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0215 · Cited by 459

Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma

Xie, Y., Akpınarlı, A., Maris, C. H., Hipkiss, E. L., Lane, M. V., Kwon, E. M., Muranski, P. J., Restifo, N. P., & Antony, P. A. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20091921 · Cited by 473

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Coit, D. G., Thompson, J. A., Albertini, M. R., Barker, C. A., Carson, W. E., Contreras, C. M., Daniels, G. A., DiMaio, D. J., Fields, R. C., Fleming, M. D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0018 · Cited by 437

Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity

Serrels, A., Lund, T., Serrels, B., Byron, A., McPherson, R. C., von Kriegsheim, A., Gómez-Cuadrado, L., Canel, M., Muir, M., Ring, J. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.001 · Cited by 407

Cancer immunotherapy – revisited

Lesterhuis, W. J., Haanen, J. B. A. G., & Punt, C. J. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3500 · Cited by 438

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

Vargas, F. A., Furness, A. J. S., Solomon, I., Joshi, K., Mekkaoui, L., Lesko, M. H., Miranda, E., Dahan, R., Georgiou, A., Śledzińska, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.013 · Cited by 415

Treg and CTLA-4: Two intertwining pathways to immune tolerance

Walker, L. S. K. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.06.006 · Cited by 425

Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 family

Bour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391

Regulatory T Cells in Cancer

Mougiakakos, D., Choudhury, A., Lladser, Á., Kiessling, R. W., & Johansson, C. C. (2010) · Advances in cancer research · doi:10.1016/s0065-230x(10)07003-x · Cited by 413

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer

Huang, R., Francois, A., McGray, A. R., Miliotto, A. J., & Odunsi, K. O. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1249561 · Cited by 395

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 389

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers

Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0762 · Cited by 382

Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response

Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C. H. H., Joseph‐Pietras, D., Welters, M. J. P., van der Burg, S., Kapiteijn, E., Michielin, O. A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008918 · Cited by 392

At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 387

Combination immunotherapy for hepatocellular carcinoma

Rimassa, L., Finn, R. S., & Sangro, B. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.003 · Cited by 377

Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy

Marciscano, A. E. E., Ghasemzadeh, A., Nirschl, T. R., Theodros, D., Kochel, C. M., Francica, B. J., Muroyama, Y., Anders, R. A., Sharabi, A. B., Velarde, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3427 · Cited by 364

LAG-3 in Cancer Immunotherapy

Goldberg, M. V., & Drake, C. G. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_114 · Cited by 337

CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

Grosso, J. F., & Jure‐Kunkel, M. (2013) · Europe PMC (PubMed Central) · Cited by 335

Designing Vaccines Based on Biology of Human Dendritic Cell Subsets

Palucka, K., Banchereau, J., & Mellman, I. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.007 · Cited by 341

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

Ravi, R., Noonan, K. A., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., V. Artemov, A., Wysocki, P. T., Mehra, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02696-6 · Cited by 325

Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Response

Sharma, A., Subudhi, S. K., Blando, J. M., Vence, L. M., Wargo, J. A., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0402 · Cited by 317

Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade

Weber, J. S. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.005 · Cited by 309

Adaptive Immune Resistance Emerges from Tumor-Initiating Stem Cells

Miao, Y., Yang, H., Levorse, J., Yuan, S., Polak, L., Sribour, M., Singh, B., Rosenblum, M. D., & Fuchs, E. (2019) · Cell · doi:10.1016/j.cell.2019.03.025 · Cited by 299

Regulatory T cells in the treatment of disease

Sharabi, A., Tsokos, M., Ding, Y., Malek, T. R., Klatzmann, D., & Tsokos, G. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.148 · Cited by 301

Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy

Bos, P. D., Plitas, G., Rudra, D., Lee, S. Y., & Rudensky, A. Y. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130762 · Cited by 305

Safety of combining radiotherapy with immune-checkpoint inhibition

Hwang, W. L., Pike, L., Royce, T. J., Mahal, B. A. V., & Loeffler, J. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0046-7 · Cited by 299

AP-1 Transcription Factors as Regulators of Immune Responses in Cancer

Atsaves, V., Leventaki, V., Rassidakis, G. Z., & Claret, F. X. (2019) · Cancers · doi:10.3390/cancers11071037 · Cited by 295

The immune system in cancer metastasis: friend or foe?

Janssen, L. M. E., Ramsay, E. E., Logsdon, C. D., & Overwijk, W. W. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0283-9 · Cited by 298

Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies

Cervantes‐Villagrana, R. D., Albores‐García, D., Cervantes-Villagrana, A. R., & García-Acevez, S. J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0205-z · Cited by 311

Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury

Zen, Y., & Yeh, M. M. (2018) · Modern Pathology · doi:10.1038/s41379-018-0013-y · Cited by 266

Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti–CTLA-4 Therapy

Waitz, R., Solomon, S. B., Petre, E. N., Trumble, A. E., Fassò, M., Norton, L., & Allison, J. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1782 · Cited by 288

Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication

Quezada, S. A., Peggs, K. S., Simpson, T. R., & Allison, J. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01007.x · Cited by 290

Therapeutic cancer vaccines: Are we there yet?

Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271

Advances in targeting cell surface signalling molecules for immune modulation

Yao, S., Zhu, Y., & Chen, L. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3877 · Cited by 271

Recent strategies for nano-based PTT combined with immunotherapy: from a biomaterial point of view

Huang, X., Lu, Y., Guo, M., Du, S., & Han, N. (2021) · Theranostics · doi:10.7150/thno.56482 · Cited by 267

Immunotherapy in Melanoma: Recent Advances and Future Directions

Knight, A., Karapetyan, L., & Kirkwood, J. M. (2023) · Cancers · doi:10.3390/cancers15041106 · Cited by 281

Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation

Cohen, A. D., Schaer, D., Liu, C., Li, Y., Hirschhorn-Cymerman, D., Kim, S. C., Diab, A. K., Rizzuto, G. A., Duan, F., Perales, M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010436 · Cited by 266

PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer

Kansy, B., Concha‐Benavente, F., Srivastava, R. M., Jie, H.-B., Shayan, G., Lei, Y. L., Moskovitz, J. M., Moy, J. D., Li, J., Brandau, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3167 · Cited by 258

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma

Khair, D. O., Bax, H. J., Mele, S., Crescioli, S., Pellizzari, G., Khiabany, A., Nakamura, M., Harris, R. J. C., French, E., Hoffmann, R. M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00453 · Cited by 252

Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy

Callahan, M. K., Wolchok, J. D., & Allison, J. P. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.001 · Cited by 248

Cardiotoxicity of immune checkpoint inhibitors

Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 247

Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells

Śledzińska, A., Vila de Mucha, M., Bergerhoff, K., Hotblack, A., Demane, D. F., Ghorani, E., Akarca, A. U., Marzolini, M. A. V., Solomon, I., Vargas, F. A., et al. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.007 · Cited by 228

Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy

Hoos, A., Ibrahim, R. A., Korman, A. J., Abdallah, K. A., Berman, D., Shahabi, V., Chin, K. M., Canetta, R. M., & Humphrey, R. W. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.015 · Cited by 248

Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions

Hato, T., Goyal, L., Greten, T. F., Duda, D. G., & Zhu, A. X. (2014) · Hepatology · doi:10.1002/hep.27246 · Cited by 242

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal

Linch, S. N., McNamara, M. J., & Redmond, W. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00034 · Cited by 243

Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy

Wang, H., Franco, F., & Ho, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.06.005 · Cited by 233

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Papachristofilou, A., Hipp, M., Klinkhardt, U., Früh, M., Sebastian, M., Weiß, C., Pless, M., Cathomas, R. L., Hilbe, W., Pall, G., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0520-5 · Cited by 233

Therapeutic opportunities for manipulating TReg cells in autoimmunity and cancer

von Boehmer, H., & Daniel, C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3683 · Cited by 230

IL-12 initiates tumor rejection via lymphoid tissue–inducer cells bearing the natural cytotoxicity receptor NKp46

Eisenring, M., Berg, J. V., Kristiansen, G., Saller, E., & Becher, B. (2010) · Nature Immunology · doi:10.1038/ni.1947 · Cited by 226

CAR T‐Cell‐Based gene therapy for cancers: new perspectives, challenges, and clinical developments

Jogalekar, M. P., Rajendran, R. L., Khan, F., Dmello, C., Gangadaran, P., & Ahn, B.-C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925985 · Cited by 214

CTLA-4: Negative Regulator of the Immune Response and a Target for Cancer Therapy

Keilholz, U. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318174a4fe · Cited by 32

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

Peggs, K. S., Quezada, S. A., Korman, A. J., & Allison, J. P. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.011 · Cited by 448

CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

Grosso, J. F., & Jure‐Kunkel, M. (2013) · Europe PMC (PubMed Central) · Cited by 335

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity

Watanabe, T., Ishino, T., Ueda, Y., Nagasaki, J., Sadahira, T., Dansako, H., Araki, M., & Togashi, Y. (2023) · Cancer Science · doi:10.1111/cas.15756 · Cited by 53

Targeting interference of CTLA-4 co-inhibition to tumour specific T cells to enhance activity and reduce toxicity

Roddie, C. (2016) · UCL Discovery (University College London)